Related Experiment Video
Updated: Oct 8, 2025
Exploring the Two Herb Combination Strategy to Treat Injured PC12 Cells
Published on: November 18, 2022
[Research progress on Chinese medicinal material-derived active polypeptides against ischemic cardiovascular and
Ao-Ao Wang1, Lei Li1, Ying Li1
1National Clinical Research Center of Traditional Chinese Medicine for Cardiovascular Diseases, Beijing Key Laboratory of Chinese Materia Pharmacology, Xiyuan Hospital, China Academy of Chinese Medical Sciences Beijing 100091, China.
Insights
Chinese medicinal material-derived polypeptides show promise for treating ischemic cardiovascular and cerebrovascular diseases. Further research into their targets and mechanisms can support clinical development.
Area of Science:
- Cardiovascular and Cerebrovascular Diseases
- Pharmacology
- Traditional Chinese Medicine
Background:
- Ischemic cardiovascular and cerebrovascular diseases pose significant global health risks due to high morbidity and mortality.
- Vascular stenosis, atherosclerosis, and infarction leading to reduced blood supply are common causes.
- Complex pathological mechanisms include oxidative stress, calcium overload, inflammation, apoptosis, and autophagy.
Purpose of the Study:
- To review the targets and action mechanisms of Chinese medicinal material-derived polypeptides for treating ischemic cardiovascular and cerebrovascular diseases.
- To provide support for the research, clinical development, and application of these polypeptides.
Main Methods:
- Literature review of existing research on Chinese medicinal material-derived polypeptides.
- Analysis of identified targets and action mechanisms.
- Comparison with existing protein drugs like recombinant tissue plasminogen activator (rt-PA) and urokinase.
Main Results:
- Peptide drugs, including those from Chinese medicinal materials, offer advantages such as strong biological activity, high target specificity, biochemical diversity, and low toxicity.
- Chinese medicinal materials exhibit multi-component and multi-target therapeutic effects against ischemic diseases.
- Research and development of these specific peptides are currently in the initial stages.
Conclusions:
- Chinese medicinal material-derived polypeptides represent a promising therapeutic avenue for ischemic cardiovascular and cerebrovascular diseases.
- Understanding their specific targets and mechanisms is crucial for advancing their clinical application.
- Further research is warranted to fully harness the potential of these natural compounds.
Abstract:
Ischemic cardiovascular and cerebrovascular diseases threatening human health and survival have high morbidity and mortality. The common cause of them is reduced blood supply caused by vascular stenosis, atherosclerosis, and infarction. However,the pathological processes of ischemic cardiovascular and cerebrovascular diseases are complex, involving oxidative stress, calcium overload, inflammation, apoptosis, autophagy and other mechanisms. Protein drugs such as recombinant tissue plasminogen activator(rt-PA) and urokinase have been proved with excellent therapeutic effects and huge economic and social benefits in the clinical treatment and interventional therapy. Among them, peptide drugs have shown unique advantages and potential prospects owing to their strong biological activity, high target specificity, biochemical diversity, and low toxicity. Chinese medicinal materials, characterized by multi-component and multi-target therapy, have also shown excellent clinical efficacy against ischemic cardiovascular and cerebrovascular diseases. However, the research and development of related peptides in Chinese medicinal materials is at the initial stage. Therefore, this paper reviewed the targets and action mechanisms of a variety of Chinese medicinal material-derived polypeptides with activities against ischemic cardiovascular and cerebrovascular diseases, aiming to provide support for the in-depth research as well as the clinical development and application of these polypeptides.
